Myeloproliferative neoplasm

4 trials 2 recruiting MedDRA PT
4 Registered trials
2 Recruiting
3 Unique sponsors
2 Unique IMPs
4 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
— ATC code not specified 3
Mechanism of action (INN-stem analysis)
BCL-2 inhibitor 1 substance
Kinase inhibitor 1 substance
Phase I (Other): 4

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase I (Other)

4 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    NAVITOCLAX; RUXOLITINIB
    2023-507274-40-00 6 countries 2021 n=60 Orphan
    Ended
  • Hutchmed Ltd. Commercial
    IMP not specified
    2024-516369-36-00 1 country 2021 n=37
    Ended
  • Incyte Corp. Commercial
    IMP not specified
    2023-506145-38-00 3 countries 2021 n=44
    Recruiting
  • Incyte Corp. Commercial
    IMP not specified
    2024-520353-21-00 4 countries 2026 n=120
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Incyte Corp. Commercial 2 Phase I (Other) 2
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase I (Other) 0
Hutchmed Ltd. Commercial 1 Phase I (Other) 0
New trials by year
2021
3
2026
1
← All indication landscapes